U-NEURON (6973) leverages its world-leading patented amniotic fluid stem cell technology to address the multi-billion-dollar blue ocean market of male erectile dysfunction (ED).
According to statistics from the Taiwan Urological Association, approximately 1.7 million men over the age of 40 in Taiwan experience erectile dysfunction (ED).

Capitalizing on this massive market demand, U-NEURON (Stock Code: 6973)—the first company in Taiwan to hold patents for amniotic fluid stem cell culture technology—is unlocking this multi-billion-dollar market by advancing clinical research for its stem cell and exosome drug pipeline (Engine A).

 

U-NEURON Chairman Dr. Frank Chien emphasized that existing therapies, such as Viagra, fail to reverse underlying neural damage. In contrast, U-NEURON’s proprietary amniotic fluid stem cell candidate, “UA002,” is designed to repair damaged tissues and nerves. Dr.

Chien confidently noted: “Anyone dissatisfied with Viagra is a potential customer for us.” U-NEURON is the first company globally to obtain a U.S. patent for amniotic fluid stem cell isolation and culture technology, and stands as the only biotech company in Asia utilizing amniotic fluid stem cells as its core R&D driver.

Chairman Dr. Frank Chien stated that U-NEURON has long been deeply rooted in regenerative medicine, accumulating an extensive patent portfolio in amniotic fluid stem cells and exosomes.

 

Building on this proprietary R&D platform, the company has established a diversified product pipeline spanning novel therapeutics, cosmeceuticals, and functional health foods. According to a report by Precedence Research, the global ED therapeutics market is projected to expand at a compound annual growth rate (CAGR) of 8.69% from 2025 to 2034, reaching approximately $6.74 billion by 2034.

When combined with the sexual health supplement market, the total addressable male ED market exceedsUS$10billion. While the global ED market is vast, existing oral medications (such as Viagra) merely offer short-term symptom relief via temporary vasodilation. These treatments carry potential cardiovascular risks and side effects, and cannot repair damaged nerves or blood vessels.

U-NEURON’s novel candidate UA002 aims to achieve fundamental tissue and neural restoration via a single intracavernosal injection, offering the potential for a curative solution. U-NEURON Chairman Dr. Frank Chien (center) previously served in the semiconductor industry. He forms the company’s core leadership triad alongside President Dr. Hsiao-Min Huang (left) and Vice President & COO Shin-Yi Chuang (right). UA002 will be administered via localized injections at the base of the penis, requiring only 1 to 2 doses per year.

20260325bus001
Dr. Chien estimates that its pricing will be approximately ten times that of Viagra.

In addition to its therapeutic pipeline, U-NEURON leverages its proprietary technologies for high-end medical aesthetics, skincare, and functional nutraceuticals.

Through a strategic partnership with major shareholder Chlitina Holding Limited (4137), U-NEURON’s products have successfully entered direct sales networks and major domestic e-commerce platforms, driving stable operational momentum. Drawing from his extensive semiconductor design and manufacturing background, Dr.

Chien introduced the “i-ExoCraft® Intelligent Exosome Design & Manufacturing Platform,” ushering the exosome industry into a new era modeled on the “Design House × Foundry” paradigm. Driven by the dual-engine business model combining exosome therapeutics with cosmeceuticals and functional foods, U-NEURON has effectively overcome the traditional challenge of long development cycles faced by conventional drug developers, achieving exponential revenue growth in 2025.

As stem cell and exosome technologies accelerate commercial implementation and expand brand partnerships, institutional investors project that company revenues will continue to double in 2026.

https://www.mirrormedia.mg/story/20260325bus001